Emphysema destroys the air sacs in your lungs, making it progressively harder to get oxygen into your blood. Long-term oxygen therapy (LTOT) is one of only two treatments proven to extend life in severe cases.
The evidence for oxygen therapy in emphysema goes back over 40 years to two landmark trials that changed how doctors treat advanced COPD. Since then, the prescribing criteria have been refined, delivery systems have improved, and researchers have gained a clearer picture of who benefits most and who does not.
This guide covers the clinical evidence, when oxygen is prescribed, how it works in practice, and what living with supplemental oxygen actually looks like for emphysema patients.
Key Takeaways
- Two landmark trials (NOTT 1980, MRC 1981) proved that continuous oxygen therapy reduces mortality in severe emphysema by 30-40%
- Oxygen is prescribed when resting PaO2 falls to 55 mmHg or below (or 56-59 mmHg with complications like cor pulmonale)
- More hours of oxygen use per day means better outcomes: continuous use (15+ hours) beats nocturnal-only therapy
- The 2016 LOTT trial found no survival benefit for patients with only moderate desaturation, narrowing who should use oxygen
- Oxygen therapy does not cure emphysema or reverse lung damage, but it reduces strain on the heart and improves daily function
Why Emphysema Causes Chronic Low Oxygen
Emphysema is a form of chronic obstructive pulmonary disease (COPD) in which the alveoli (tiny air sacs where gas exchange happens) are gradually destroyed. As more alveoli are lost, the total surface area available for oxygen absorption shrinks. The remaining tissue loses its elasticity, trapping stale air and making exhalation difficult.
The result is chronic hypoxemia: persistently low blood oxygen levels. In mild emphysema, oxygen may drop only during exercise or sleep. In moderate to severe disease, resting oxygen levels fall below the threshold needed to support normal organ function. The heart compensates by working harder to pump oxygen-poor blood, eventually leading to pulmonary hypertension and right-sided heart failure (cor pulmonale).
Supplemental oxygen does not repair damaged alveoli. It compensates for the reduced gas exchange by increasing the concentration of oxygen in each breath, so the remaining lung tissue can absorb more of it.
The Evidence: NOTT and MRC Trials
The case for long-term oxygen therapy in emphysema rests primarily on two randomized controlled trials from the early 1980s. These remain the foundation of every clinical guideline on the topic.
NOTT Trial (1980)
The Nocturnal Oxygen Therapy Trial enrolled 203 patients with hypoxemic COPD across six U.S. centers. Patients were randomized to either continuous oxygen therapy (averaging 19+ hours per day) or nocturnal-only oxygen (12 hours per day).1
After a mean follow-up of 19.3 months, the mortality rate in the nocturnal-only group was 1.94 times higher than in the continuous group (p = 0.01). At 24 months, survival was 87% in the continuous group versus 59% in the nocturnal group. The benefit was most pronounced in patients with carbon dioxide retention and those with more severe baseline hypoxemia.
MRC Trial (1981)
The Medical Research Council trial, conducted in the UK, enrolled 87 COPD patients with severe resting hypoxemia. Patients were randomized to either oxygen for at least 15 hours per day or no supplemental oxygen.2
At five years, survival was 55% in the oxygen group versus 33% in the no-oxygen group. The MRC trial confirmed that long-term oxygen use reduces mortality in severe COPD, and together with NOTT, established that more daily hours of oxygen use translates to better survival.
“At 24 months of oxygen therapy, survival was 87% in the continuous group versus 59% in the nocturnal-only group.”
Nocturnal Oxygen Therapy Trial Group, Annals of Internal Medicine, 1980
LOTT Trial (2016)
The Long-Term Oxygen Treatment Trial addressed a question the earlier trials did not: does oxygen help patients with only moderate desaturation? The LOTT trial enrolled 738 patients with stable COPD and moderate resting desaturation (SpO2 89-93%) or exercise-induced desaturation.3
After a median follow-up of 18.4 months, there was no difference in time to death or first hospitalization between the oxygen and no-oxygen groups. This trial narrowed the clinical indication. Oxygen therapy provides a survival benefit for severe hypoxemia but not for moderate desaturation.
When Oxygen Is Prescribed
Based on the trial evidence and current guidelines (ATS, ERS, GOLD), LTOT is indicated when:4
| Criterion | Threshold |
|---|---|
| Resting PaO2 | 55 mmHg or below (SpO2 ~88% or below) |
| Resting PaO2 with complications | 56-59 mmHg with cor pulmonale, polycythemia, or pulmonary hypertension |
| Exercise desaturation | SpO2 drops below 88% during exertion (ambulatory oxygen may be prescribed) |
| Nocturnal desaturation | SpO2 below 88% for more than 30% of sleep time |
Importantly, the prescription should be based on stable disease. Measurements taken during an acute exacerbation may not reflect the patient’s true baseline. Most guidelines recommend reassessing oxygen needs 60-90 days after an exacerbation before committing to long-term therapy.
Flow Rates and Delivery
The typical starting flow rate for LTOT is 1-2 liters per minute (LPM) via nasal cannula. The goal is to maintain SpO2 at or above 90% (PaO2 at or above 60 mmHg). Flow rates may need to increase during sleep and exercise, when oxygen demand rises.
Delivery systems include:
- Stationary concentrators: Electric units that extract oxygen from room air. Used at home. Cost $300-2,000 or covered by insurance/Medicare.
- Portable concentrators: Battery-powered units for mobility. Weigh 3-10 lbs. Deliver pulse-dose or continuous flow depending on the model.
- Compressed gas cylinders: Traditional tanks. Heavy but reliable. Used as backup or for higher flow rates.
- Liquid oxygen systems: Compact portable units that hold more oxygen per volume. Less common now due to cost and maintenance.
Most patients use a stationary concentrator at home and a portable unit when out. Medicare and most insurers cover LTOT equipment when prescribing criteria are met.
Does Oxygen Slow Disease Progression?
Oxygen therapy does not slow the rate of lung function decline (FEV1 loss) in emphysema. The survival benefit comes from reducing the cardiovascular complications of chronic hypoxemia, specifically pulmonary hypertension and right heart failure. It also reduces the workload on the diaphragm and respiratory muscles.
Patients who use oxygen consistently report improvements in exercise tolerance, sleep quality, and cognitive function. Several studies have documented reduced hospital readmissions in patients adherent to LTOT, though separating the effect of oxygen from better overall disease management is difficult.5
For patients with emphysema exploring additional oxygen-based therapies beyond supplemental oxygen, hyperbaric oxygen therapy for COPD is a separate modality with its own evidence base.
Ambulatory Oxygen
Ambulatory oxygen refers to portable oxygen used during physical activity. Some patients have adequate resting oxygen levels but desaturate significantly during walking or exercise.
The evidence for ambulatory oxygen is weaker than for continuous LTOT. A 2016 Cochrane review found modest improvements in exercise capacity but no clear survival benefit in patients who desaturate only on exertion.6 Despite this, many patients report subjective improvement in breathlessness and activity tolerance.
Ambulatory oxygen is most useful for patients who want to remain physically active and participate in pulmonary rehabilitation. The key is matching the flow rate to the activity level. Walking may require 2-4 LPM while resting needs only 1-2 LPM.
Nocturnal Oxygen
Some emphysema patients maintain acceptable oxygen levels during the day but desaturate during sleep, particularly during REM sleep when breathing becomes shallower and more irregular. Nocturnal desaturation is associated with pulmonary hypertension, arrhythmias, and poor sleep quality.
Nocturnal oxygen can be prescribed specifically for this pattern, but the evidence base is limited. The NOTT trial showed that nocturnal-only oxygen was better than nothing but significantly worse than continuous use for mortality reduction.1
Pulmonary Rehabilitation Alongside Oxygen
Oxygen therapy and pulmonary rehabilitation are complementary. Pulmonary rehab (structured exercise training, breathing techniques, education) improves exercise capacity, reduces breathlessness, and decreases hospital admissions in COPD patients. When combined with appropriate oxygen supplementation during exercise, patients can train at higher intensities and achieve better conditioning.
Current guidelines recommend pulmonary rehabilitation for all COPD patients with significant symptoms, regardless of whether they use supplemental oxygen. For oxygen-dependent patients, supplemental oxygen during rehabilitation sessions is standard practice.
Living with Oxygen and Emphysema
Adherence is the biggest challenge. Studies consistently show that many patients prescribed LTOT use it fewer hours than recommended. The average daily use in real-world studies is 13-15 hours, below the 15+ hours associated with maximum survival benefit.5
Common barriers include:
- Discomfort from nasal cannula (dryness, skin irritation)
- Embarrassment or social stigma of wearing oxygen in public
- Equipment noise (concentrators) disrupting sleep
- Reduced mobility when tethered to stationary units
- Fear of oxygen dependence (unfounded since the lungs do not “get used to” supplemental oxygen)
Practical solutions include using a humidifier bottle on the concentrator, trying different cannula styles, upgrading to quieter concentrator models, and using portable units to maintain normal activities. The evidence is clear that more hours means better outcomes, so strategies to increase daily use are worth pursuing.
Safety Considerations
Supplemental oxygen increases fire risk. Oxygen does not burn, but it makes other materials ignite more easily and burn more intensely. Patients must stay at least 6 feet from open flames, not smoke while using oxygen, and keep equipment away from heat sources.
Over-oxygenation is a theoretical concern in some COPD patients with chronic CO2 retention (hypercapnic respiratory failure). Excessive oxygen can suppress the hypoxic ventilatory drive and worsen CO2 retention. This is managed by titrating flow rates carefully and monitoring with arterial blood gases, not by withholding necessary oxygen.
Sources
- Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391-398. doi:10.7326/0003-4819-93-3-391
- Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981;1(8222):681-686. doi:10.1016/S0140-6736(81)91970-X
- Albert RK, Au DH, Blackford AL, et al. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med. 2016;375(17):1617-1627. doi:10.1056/NEJMoa1604344
- Jacobs SS, Krishnan JA, Engel MK, et al. Long-term oxygen therapy: current evidence and practical, day-to-day considerations. Chest. 2019;155(4):833-842. doi:10.1016/j.chest.2019.01.005
- Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD001744. doi:10.1002/14651858.CD001744.pub2
- Bradley JM, O’Neill B. Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD004356. doi:10.1002/14651858.CD004356.pub3
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
